Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Pathologic analysis of non-neoplastic parenchyma in renal cell carcinoma: a comprehensive observation in radical nephrectomy specimens

Authors: Xun Wang, Qiang Liu, Wen Kong, Jiwei Huang, Yonghui Chen, Yiran Huang, Jin Zhang

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

This study provides a comprehensive examination of the histological features of non-neoplastic parenchyma in renal cell carcinoma (RCC). We prospectively collected radical nephrectomy (RN) specimens, to analyze the histological changes within peritumoral and distant parenchyma.

Methods

Data of patients who underwent RN and had no known history of diabetes, hypertension, hyperlipidemia, or chronic kidney disease etc., were prospectively collected. Tumor pseudo-capsule (PC), and parenchyma within 2 cm from tumor margin, were pathologically assessed. The parenchyma beyond PC or tumor margin was divided into 20 subsections of 1 mm in width. Histological changes, including chronic inflammation, glomerulosclerosis, arteriosclerosis and nephrosclerosis, were given scores of 0, 1, 2 or 3 for each subsection of each specimen, according to their severity. The 20 subsections of each specimen were further divided into four groups according to the distance from the tumor edge (group 1: 0–2 mm; group 2: 2–5 mm; group 3: 5–10 mm; group 4: 10–20 mm), to better compare the peritumoral parenchyma with the distant parenchyma.

Results

In total, 53 patients were involved in this study. All tumors were confirmed RCCs (clear cell vs. papillary vs. chromophobe were 83% vs. 5.7% vs. 11.3%, respectively), with a mean size of 5.6 cm. Histological changes were more severe in peritumoral parenchyma close to PC or tumor edge (0–5 mm), and less common within parenchyma more distant from the tumor (5–20 mm) (p < 0.001). chronic inflammation and nephrosclerosis were the most common changes especially in peritumoral parenchyma (0-2 mm). PC was present in 49 tumors (92.5%), and PC invasion occurred in 5 cases (10.2%). Mean PC thickness was 0.7 mm. PCs were more likely to be present in clear cell RCC or papillary RCC than in chromophobe RCC (100% vs. 100% vs. 33.3%, respectively; p < 0.001).

Conclusions

Most RCCs have a well-developed PC, especially clear cell RCC. Histological changes mainly occur in peritumoral parenchyma, being rather uncommon in distant parenchyma. A compression band filled with severe histological changes was typically observed in renal parenchyma close to the tumor. Its preservation while performing an enucleation margin may not be entirely necessary.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brandina R, Moreira Leite KR, Gregorio EP, Fernandes KB, Srougi M, et al. Histologic abnormalities in non-neoplastic renal parenchyma and the risk of chronic kidney disease following radical nephrectomy. Urology. 2017;100:158–62.CrossRefPubMed Brandina R, Moreira Leite KR, Gregorio EP, Fernandes KB, Srougi M, et al. Histologic abnormalities in non-neoplastic renal parenchyma and the risk of chronic kidney disease following radical nephrectomy. Urology. 2017;100:158–62.CrossRefPubMed
2.
go back to reference Henriksen KJ, Meehan SM, Chang A. Nonneoplastic kidney diseases in adult tumor nephrectomy and Nephroureterectomy specimens: common, harmful, yet underappreciated. Arch Pathol Lab Med. 2009;133:1012–225.PubMed Henriksen KJ, Meehan SM, Chang A. Nonneoplastic kidney diseases in adult tumor nephrectomy and Nephroureterectomy specimens: common, harmful, yet underappreciated. Arch Pathol Lab Med. 2009;133:1012–225.PubMed
3.
go back to reference Sarsik B, Simsir A, Yilmaz M, Yörükoglu K, Sen S. Spectrum of nontumoral renal pathologies in tumor nephrectomies: nontumoral renal parenchyma changes. Ann Diagn Pathol. 2013;17:176–82.CrossRefPubMed Sarsik B, Simsir A, Yilmaz M, Yörükoglu K, Sen S. Spectrum of nontumoral renal pathologies in tumor nephrectomies: nontumoral renal parenchyma changes. Ann Diagn Pathol. 2013;17:176–82.CrossRefPubMed
4.
go back to reference Garcia-Roig M, Gorin MA, Parra-Herran C, Garcia-Buitrago M, Kava BR, Jorda M, et al. Pathologic evaluation of non-neoplastic renal parenchyma in partial nephrectomy specimens. World J Urol. 2013;31:835–9.CrossRefPubMed Garcia-Roig M, Gorin MA, Parra-Herran C, Garcia-Buitrago M, Kava BR, Jorda M, et al. Pathologic evaluation of non-neoplastic renal parenchyma in partial nephrectomy specimens. World J Urol. 2013;31:835–9.CrossRefPubMed
5.
go back to reference Gorin MA, Garcia-Roig M, Garcia-Buitrago M, Parra-Herran C, Jorda M, Ciancio G, et al. Atherosclerosis within the non-neoplastic margin of partial nephrectomy specimens: implications for medical management. World J Urol. 2013;31:1531–4.CrossRefPubMed Gorin MA, Garcia-Roig M, Garcia-Buitrago M, Parra-Herran C, Jorda M, Ciancio G, et al. Atherosclerosis within the non-neoplastic margin of partial nephrectomy specimens: implications for medical management. World J Urol. 2013;31:1531–4.CrossRefPubMed
6.
go back to reference Minervini A, Rosaria Raspollini M, Tuccio A, Di Cristofano C, Siena G, Salvi M, et al. Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation. Urol Oncol. 2014;32:50.e15–22.CrossRef Minervini A, Rosaria Raspollini M, Tuccio A, Di Cristofano C, Siena G, Salvi M, et al. Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation. Urol Oncol. 2014;32:50.e15–22.CrossRef
7.
go back to reference Bijol V, Batal I. Non-neoplastic pathology in tumor nephrectomy specimens. Surg Pathol Clin. 2014;7(3):291–305.CrossRefPubMed Bijol V, Batal I. Non-neoplastic pathology in tumor nephrectomy specimens. Surg Pathol Clin. 2014;7(3):291–305.CrossRefPubMed
8.
go back to reference Azhar RA, de Castro Abreu AL, Broxham E, Sherrod A, Ma Y, Cai J, et al. Histological analysis of the kidney tumor-parenchyma interface. J Urol. 2015;193:415–22.CrossRefPubMed Azhar RA, de Castro Abreu AL, Broxham E, Sherrod A, Ma Y, Cai J, et al. Histological analysis of the kidney tumor-parenchyma interface. J Urol. 2015;193:415–22.CrossRefPubMed
9.
go back to reference Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, et al. Does the renal parenchyma adjacent to the tumor contribute to kidney function? A critical analysis of glomerular viability in partial nephrectomy specimens. Urology. 2016;87:114–9.CrossRefPubMed Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, et al. Does the renal parenchyma adjacent to the tumor contribute to kidney function? A critical analysis of glomerular viability in partial nephrectomy specimens. Urology. 2016;87:114–9.CrossRefPubMed
10.
go back to reference Brandina R, Moreira Leite KR, Gregorio EP, Fernandes KB, Srougi M. Histologic abnormalities in non-neoplastic renal parenchyma and the risk of chronic kidney disease following radical nephrectomy. Urology. 2017;100:158–62.CrossRefPubMed Brandina R, Moreira Leite KR, Gregorio EP, Fernandes KB, Srougi M. Histologic abnormalities in non-neoplastic renal parenchyma and the risk of chronic kidney disease following radical nephrectomy. Urology. 2017;100:158–62.CrossRefPubMed
11.
go back to reference Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798–805.CrossRefPubMed Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798–805.CrossRefPubMed
12.
go back to reference Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.CrossRefPubMed Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.CrossRefPubMed
13.
go back to reference Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. Chicago: Springer-Verlag; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. Chicago: Springer-Verlag; 2010.
14.
go back to reference Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005. Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005.
15.
go back to reference Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.CrossRefPubMed Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.CrossRefPubMed
16.
go back to reference Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol. 2011;186:405–10.CrossRefPubMed Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol. 2011;186:405–10.CrossRefPubMed
17.
go back to reference Kotamarti S, Rothberg MB, Danzig MR, Levinson J, Saad S, Korets R, et al. Increasing volume of non-neoplastic parenchyma in partial nephrectomy specimens is associated with chronic kidney disease upstaging. Clin Genitourin Cancer. 2015;13:239–43.CrossRefPubMed Kotamarti S, Rothberg MB, Danzig MR, Levinson J, Saad S, Korets R, et al. Increasing volume of non-neoplastic parenchyma in partial nephrectomy specimens is associated with chronic kidney disease upstaging. Clin Genitourin Cancer. 2015;13:239–43.CrossRefPubMed
18.
go back to reference Sutherland SE, Resnick MI, Maclennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol. 2002;167:61–4.CrossRefPubMed Sutherland SE, Resnick MI, Maclennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol. 2002;167:61–4.CrossRefPubMed
19.
go back to reference Süer E, Ergün G, Baltaci S, Bedük Y. Does renal capsular invasion have any prognostic value in localized renal cell carcinoma? J Urol. 2008;180:68–71.CrossRefPubMed Süer E, Ergün G, Baltaci S, Bedük Y. Does renal capsular invasion have any prognostic value in localized renal cell carcinoma? J Urol. 2008;180:68–71.CrossRefPubMed
20.
go back to reference Minervini A, di Cristofano C, Lapini A, Marchi M, Lanzi F, Giubilei G, et al. Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma. Eur Urol. 2009;55:1410–8.CrossRefPubMed Minervini A, di Cristofano C, Lapini A, Marchi M, Lanzi F, Giubilei G, et al. Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma. Eur Urol. 2009;55:1410–8.CrossRefPubMed
21.
go back to reference Cho HJ, Kim SJ, Ha US, Hong SH, Kim JC, Choi YJ, et al. Prognostic value of capsular invasion for localized clear- cell renal cell carcinoma. Eur Urol. 2009;56:1006–12.CrossRefPubMed Cho HJ, Kim SJ, Ha US, Hong SH, Kim JC, Choi YJ, et al. Prognostic value of capsular invasion for localized clear- cell renal cell carcinoma. Eur Urol. 2009;56:1006–12.CrossRefPubMed
Metadata
Title
Pathologic analysis of non-neoplastic parenchyma in renal cell carcinoma: a comprehensive observation in radical nephrectomy specimens
Authors
Xun Wang
Qiang Liu
Wen Kong
Jiwei Huang
Yonghui Chen
Yiran Huang
Jin Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3849-5

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine